AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Inclusion Criteria: * Histologically confirmed low-grade neuroendocrine neoplasm * Measurable disease * Radiographic evidence of disease progression after any prior systemic therapy, chemoembolization, bland embolization, or observation, defined by either of the following: * Appearance of a new lesion * At least 20% increase in the longest diameter of any previously documented lesion or in the sum of the longest diameters of multiple lesions * Tissue block from original diagnostic or surgical specimen required * Concurrent stable-dose octreotide acetate required * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Negative pregnancy test * Fertile patients must use effective contraception * Must be able to receive a contrast-enhanced CT scan * Absolute neutrophil count ≥ 1,000/mm³ * Platelet count ≥ 75,000/mm³ * Hemoglobin level ≥ 8.0 g/dL * Bilirubin ≤ 2.0 times upper limit of normal (ULN) * Aspartate aminotransferase (AST) ≤ 3 times ULN (5 times ULN if liver metastases are present) * Left Ventricular Ejection Fraction (LVEF) ≥ institutional lower limit of normal as evaluated by echocardiography or multigated acquisition (MUGA) scan * No history of uncontrolled hypertension (resting blood pressure \> 150/90 mm Hg) * Antihypertensive medications allowed if patients is stable on their current dose * One prior systemic chemotherapy regimen for low-grade neuroendocrine neoplasm allowed * Chemoembolization is not considered systemic chemotherapy * At l…